Importance of Acute Lymphoblastic Leukemia-type Therapy for Bilineal Acute LeukemiaNakagawa, Shunsuke MD; Okamoto, Yasuhiro MD; Kodama, Yuichi MD, PhD; Nishikawa, Takuro MD, PhD; Tanabe, Takayuki MD; Kawano, Yoshifumi MD, PhDJournal of Pediatric Hematology/Oncology: September 05, 2018 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/MPH.0000000000001309 Clinical and Laboratory Observations: PDF Only Buy PAP Abstract Author InformationAuthors Article MetricsMetrics We examined 3 pediatric patients with bilineal acute leukemia. Patient 1 with B-cell acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) with B-ALL dominance responded well to prednisolone and ALL-type induction therapy. Patients 2 and 3 with T-ALL and AML with AML dominance responded poorly to prednisolone. Patient 2 was resistant to AML-type therapy; patient 3 was resistant to ALL-type induction therapy until day 15. However, all 3 patients eventually achieved complete remission after ALL-type induction therapy. Thus, ALL-type induction therapy should be initiated for bilineal acute leukemia even with AML-dominant, poor prednisolone response, or poor early response features. Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan The authors declare no conflict of interest. Reprints: Yasuhiro Okamoto, MD, Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City 890-8520, Japan (e-mail: email@example.com). Received March 10, 2018 Accepted August 8, 2018 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.